Idorsia-led Portfolio
| Compound | Mechanism of action | Target indication | Status | More Information |
|
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France; |
|
| TRYVIO™ (aprocitentan) |
Dual endothelin receptor antagonist |
Systemic hypertension in combination with other antihypertensive drugs | Approved in the US, launch planned for H2 2024 | |
| JERAYGO™ (aprocitentan) |
Dual endothelin receptor antagonist |
Resistant hypertension in combination with other antihypertensive drugs | Positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) received in April 2024 - European Commission decision expected in approx. 2 months | Investor webcast |
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 primary endpoint not met, |
|
|
ACT-1004-1239 |
ACKR3/CXCR7 antagonist |
Demyelinating diseases including multiple sclerosis |
Phase 2 in preparation |
|
|
Sinbaglustat |
GBA2/GCS inhibitor |
Rare lysosomal storage disorders |
Phase 1 complete |
|
|
ACT-777991 |
CXCR3 antagonist |
Recent-onset Type 1 diabetes |
Phase 1 complete |
|
|
ACT-1014-6470 |
C5aR1 antagonist |
Immune-mediated disorders |
Phase 1 |
|
|
IDOR-1117-2520 |
Undisclosed |
Immune-mediated disorders |
Phase 1 |
|
| IDOR-1134-2831 |
Synthetic glycan vaccine |
Clostridium difficile infection |
Phase 1 in preparation |